FunPep Company Limited [4881.T]
TOKYO, Jun 01 (Pulse News Wire) – FunPep Company Limited (4881.T) announced today the commencement of joint research with Crafton Biotechnology Co., Ltd. to develop therapeutic mRNA vaccines utilizing antibody-inducing peptide technology.
Under the agreement, FunPep will focus on efficacy evaluation while Crafton Biotechnology will handle the synthesis of designed mRNA vaccines. Both companies aim to integrate FunPep's antibody-inducing peptide technology with Crafton’s innovative mRNA drug development platform, PureCap®, to create novel therapeutic mRNA vaccines. This collaboration does not affect FunPep's forecasted research and development expenses for the fiscal year ending December 2026.
FunPep will bear the costs associated with its responsibilities within the joint research project. Crafton Biotechnology was established on March 01, 2022, based on technologies from Nagoya University and Tokyo Science University. Located at the National University Corporation Tohoku National University Organization, Nagoya University Incubation Facility, the company specializes in pharmaceutical research, development, manufacturing, sales, and technology transfer.
🟢 Confidence: High AI-translated content.